Clinically Significant Unclassified Variants in BRCA1 and BRCA2 Genes among Korean Breast Cancer Patients
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Unclassified variants (UVs) of BRCA1 and BRCA2 genes are not defined as pathogenic for breast cancer, and their clinical significance currently remains undefined. Therefore, this study was conducted to identify potentially pathogenic UVs by comparing their prevalence between breast cancer patients and controls. Materials and Methods A total of 328 breast cancer patients underwent BRCA1/2 genetic screening at the National Cancer Center of Korea. Genetic variants of BRCA genes that were categorized as unclassified according to the Breast Cancer Information Core database were selected based on allelic frequency, after which candidate variants were genotyped in 421 healthy controls. We also examined family members of the study participants. Finally, the effects of amino acid substitutions on protein structure and function were predicted in silico. Results Genetic tests revealed 33 UVs in BRCA1 and 47 in BRCA2. Among 15 candidates genotyped in healthy controls, c.5339T>C in BRCA1 and c.6029T>G, c.7522G>A in BRCA2 were not detected. Moreover, the c.5339T>C variant in the BRCA1 gene was detected in four patients with a family history of breast cancer. This nonsynonymous variant (Leu1780Pro) in the BRCA1 C-terminal domain was predicted to have an effect on BRCA1 protein structure/function. Conclusion This study showed that comparison of genotype frequency between cases and controls could help identify UVs of BRCA genes that are potentially pathogenic. Moreover, our findings suggest that c.5339T>C in BRCA1might be a pathogenic variant for patients and their families.
Abstract
Purpose Unclassified variants (UVs) of BRCA1 and BRCA2 genes are not defined as pathogenic for breast cancer, and their clinical significance currently remains undefined. Therefore, this study was conducted to identify potentially pathogenic UVs by comparing their prevalence between breast cancer patients and controls. Materials and Methods A total of 328 breast cancer patients underwent BRCA1/2 genetic screening at the National Cancer Center of Korea. Genetic variants of BRCA genes that were categorized as unclassified according to the Breast Cancer Information Core database were selected based on allelic frequency, after which candidate variants were genotyped in 421 healthy controls. We also examined family members of the study participants. Finally, the effects of amino acid substitutions on protein structure and function were predicted in silico. Results Genetic tests revealed 33 UVs in BRCA1 and 47 in BRCA2. Among 15 candidates genotyped in healthy controls, c.5339T>C in BRCA1 and c.6029T>G, c.7522G>A in BRCA2 were not detected. Moreover, the c.5339T>C variant in the BRCA1 gene was detected in four patients with a family history of breast cancer. This nonsynonymous variant (Leu1780Pro) in the BRCA1 C-terminal domain was predicted to have an effect on BRCA1 protein structure/function. Conclusion This study showed that comparison of genotype frequency between cases and controls could help identify UVs of BRCA genes that are potentially pathogenic. Moreover, our findings suggest that c.5339T>C in BRCA1might be a pathogenic variant for patients and their families.
참고문헌 (22)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012", Cancer Research and Treatment, 47(2), pp.127~141 (2015), 대한암학회[DOI]
- Futreal PA, "BRCA1 mutations in primary breast and ovarian carcinomas", Science, 266, pp.120~122 (1994)
- Miki Y, "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1", Science, 266, pp.66~71 (1994)
- Wooster R, "Identification of the breast cancer susceptibility gene BRCA2", Nature, 378, pp.789~792 (1995)
- Son BH, "Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea : the Korean Hereditary Breast Cancer(KOHBRA)Study", Breast Cancer Res Treat, 133, pp.1143~1152 (2012)
- Kang E, "The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population : recent update of the Korean Hereditary Breast Cancer(KOHBRA)study", Breast Cancer Res Treat, 151, pp.157~168 (2015)
- Szabo C, "The breast cancer information core : database design, structure, and scope", Hum Mutat, 16, pp.123~131 (2000)
- Landrum MJ, "ClinVar: public archive of relationships among sequence variation and human phenotype", Nucleic Acids Res, 42, pp.D980~D985 (2014)
- Harrison SM, "Using ClinVar as a resource to support variant interpretation", Curr Protoc Hum Genet, 89, pp.8~ (2016)
- Easton DF, "A systematic genetic assessment of 1, 433sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes", Am J Hum Genet, 81, pp.873~883 (2007)
- Calo V, "The clinical significance of unknown sequence variants in BRCA genes", Cancers(Basel), 2, pp.1644~1660 (2010)
- Spearman AD, "Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance", J Clin Oncol, 26, pp.5393~5400 (2008)
- Gomez Garcia EB, "A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history", Breast Cancer Res, 11, pp.R8~ (2009)
- Adzhubei IA, "A method and server for predicting damaging missense mutations", Nat Methods, 7, pp.248~249 (2010)
- Flanagan SE, "Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations", Genet Test Mol Biomarkers, 14, pp.533~537 (2010)
- Adzhubei I, "Predicting functional effect of human missense mutations using PolyPhen-2", Curr Protoc Hum Genet, Chapter 7 (2013)
- Sim NL, "SIFT web server: predicting effects of amino acid substitutions on proteins", Nucleic Acids Res, 40, pp.W452~W457 (2012)
- Biasini M, "SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information", Nucleic Acids Res, 42, pp.W252~W258 (2014)
- Glover JN, "Insights into the molecular basis of human hereditary breast cancer from studies of the BRCA1 BRCT domain", Fam Cancer, 5, pp.89~93 (2006)
- Campbell SJ, "Comparison of the structures and peptide binding specificities of the BRCT domains of MDC1 and BRCA1", Structure, 18, pp.167~176 (2010)
- Coquelle N, "Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition", Biochemistry, 50, pp.4579~4589 (2011)
- Zhang Y, "Rare coding variants and breast cancer risk : evaluation of susceptibility Loci identified in genome-wide association studies", Cancer Epidemiol Biomarkers Prev, 23, pp.622~628 (2014)